<article>Picsdream, India’s first marketplace for photography, has raised angel funding and Dishman Pharmaceuticals and Chemicals Ltd has raised its holding in a joint venture.</article>

Picsdream, India’s first marketplace for photography, has raised angel funding and Dishman Pharmaceuticals and Chemicals Ltd has raised its holding in a joint venture.
<h3>Picsdream raises angel funding led by Raman Roy</h3>
<a style="color: #000080;" href="http://picsdream.com/" target="_blank">Picsdream</a>, India&#8217;s marketplace for photography, has raised an undisclosed amount of angel funding led by Raman Roy, CMD Quatrro and co-founder of Indian Angel Network.
Ankit Nagori, Ex-CBO Flipkart, and Harish Natarajan, former CEO Bausch &amp; Lomb India, also participated in the round.
As part of the investment, Nagori and Natarajan have also joined the board of Picsdream. The startup will use the funding for marketing and to invest in product and technology development.
Launched in November 2015, Picsdream is run under the Group company of Addazz Online Services. It offers photographers a portal to share, showcase, monetise and securely store their work. The platform connects photographers – amateur, semi-professional and professionals &#8211; with buyers of photographs.
<h3>Dishman Pharma hikes stake in JV to 72.3%</h3>
<a style="color: #000080;" href="http://www.dishmangroup.com/home.asp" target="_blank">Dishman Pharmaceuticals and Chemicals Ltd</a> has raised its holding in local joint venture <a style="color: #000080;" href="http://www.dishmangroup.com/history.asp" target="_blank">Schutz Dishman Biotech Ltd</a> to 72.3 per cent, the company said, in a stock market disclosure.
The pharma company has acquired an additional 50 per cent stake in the JV from German partner SCHUTZ &amp; CO. BETEILIGUNGSGESELLSCHAFT MBH for €300,000 ($3,40,659 or Rs 2.25 crore).
The acquisition will help the company in backward integration for some of its existing products and for manufacturing other APIs. Post deal, Schutz Dishman will become subsidiary of the company.
Schutz Dishman Biotech manufactures bulk drugs, drug formulations and performance chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Bavla manufacturing facility.
&nbsp;
Also Read:
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/sun-pharma-buys-14-of-novartiss-brands-in-japan-for-293m-35892/" target="_blank">India’s Sun Pharma buys 14 of Novartis’s brands in Japan for $293m</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/j-star-seals-buyout-of-japans-aisei-pharmacy-35749/" target="_blank">PE firm J-Star seals buyout of Japan’s Aisei Pharmacy</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/maker-of-nutrigain-in-talks-for-pe-funding-34533/" target="_blank">India: Maker of Nutrigain, Ayurwin Pharma in talks for PE funding</a>

The pharma company has acquired an additional 50 percent stake in the JV.

India Dealbook: Picsdream raises angel funding, Dishman Pharma hikes stake in JV

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

India Dealbook: Picsdream raises angel funding, Dishman Pharma hikes stake in JV

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief